首页> 外文期刊>Molecular therapy: the journal of the American Society of Gene Therapy >Improved method of recombinant AAV2 delivery for systemic targeted gene therapy.
【24h】

Improved method of recombinant AAV2 delivery for systemic targeted gene therapy.

机译:用于系统靶向基因治疗的重组AAV2递送的改进方法。

获取原文
获取原文并翻译 | 示例
           

摘要

A major hurdle in most current gene therapy modalities is the ability to transduce target tissues at very high efficiencies that ultimately lead to therapeutic levels of transgene expression. We have developed a novel method of recombinant adeno-associated virus 2 (rAAV) delivery that results in increased vector transduction efficiencies using microspheres reversibly conjugated to rAAV vectors. We hypothesize that conjugation to microspheres should result in a higher effective concentration of vector as well as longer relative exposure time of vector to target cells as it moves through the tissue vasculature. In vitro experiments demonstrate that the same level of transduction seen with free vector can be achieved using 1% of vector when conjugated to microspheres. In addition, using magnetic microspheres, the region of infection can be targeted. In vivo, we demonstrate that microsphere-mediated delivery of rAAV vector results in higher transduction efficiencies than delivery with free vector alone when administered either intramuscularly or intravenously. Furthermore, we demonstrate targeting of transgene expression to specific tissues by retention of microsphere-bound vector in the capillary bed. These studies demonstrate a novel method to deliver rAAV vectors more effectively that could prove to be a successful alternative mode of virus-mediated human gene therapy.
机译:当前大多数基因治疗方式中的主要障碍是以非常高的效率转导靶组织的能力,最终导致转基因表达的治疗水平。我们已经开发了一种重组腺相关病毒2(rAAV)传递的新方法,该方法使用与rAAV载体可逆偶联的微球体提高了载体的转导效率。我们假设与微球的缀合应导致更高的有效载体浓度,以及当载体穿过组织脉管系统时载体对靶细胞的相对暴露时间更长。体外实验表明,与微球偶联后,使用1%的载体可实现与游离载体相同的转导水平。此外,使用磁性微球可以确定感染区域。在体内,我们证明,通过肌内或静脉内给药,微球介导的rAAV载体的递送比单独使用游离载体的递送具有更高的转导效率。此外,我们通过微球结合载体在毛细管床中的保留展示了转基因表达对特定组织的靶向。这些研究证明了一种更有效地递送rAAV载体的新颖方法,可以证明是病毒介导的人类基因治疗的成功替代模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号